Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relapsing bloodstream infections during treatment of acute leukemia.
Cattaneo C, Antoniazzi F, Tumbarello M, Skert C, Borlenghi E, Schieppati F, Cerqui E, Pagani C, Petullà M, Re A, Rossi G. Cattaneo C, et al. Among authors: schieppati f. Ann Hematol. 2014 May;93(5):785-90. doi: 10.1007/s00277-013-1965-0. Epub 2013 Nov 28. Ann Hematol. 2014. PMID: 24288110
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E, Cattaneo C, Cerqui E, Archetti S, Bertoli D, Bellotti D, Gramegna D, Soverini G, Oberti M, Schieppati F, Pagani C, Passi A, Sciumé M, Farina M, Carbone C, Crippa C, Dalceggio D, Tucci A, Rossi G. Borlenghi E, et al. Among authors: schieppati f. Hematol Oncol. 2020 Dec;38(5):754-762. doi: 10.1002/hon.2806. Epub 2020 Sep 29. Hematol Oncol. 2020. PMID: 32950042
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G. D'Adda M, et al. Among authors: schieppati f. Cancer. 2019 May 15;125(10):1674-1682. doi: 10.1002/cncr.31977. Epub 2019 Feb 1. Cancer. 2019. PMID: 30707758 Free article.
An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.
Schieppati F, Balzarini P, Fisogni S, Re A, Pagani C, Bianchetti N, Micheli L, Passi A, Ferrari S, Maifredi A, Bottelli C, Leopaldo R, Pellegrini V, Facchetti F, Rossi G, Tucci A. Schieppati F, et al. Haematologica. 2020 May;105(5):1369-1378. doi: 10.3324/haematol.2019.223891. Epub 2019 Aug 8. Haematologica. 2020. PMID: 31399522 Free PMC article.
Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.
Malagola M, Cancelli V, Skert C, Leali PF, Ferrari E, Tiburzi A, Sala ML, Donnini I, Chiusolo P, Mussetti A, Battista M, Turra A, Cattina F, Rambaldi B, Schieppati F, Polverelli N, Bernardi S, Perucca S, Marini M, Laszlo D, Savignano C, Patriarca F, Corradini P, Piccirillo N, Sica S, Bosi A, Russo D. Malagola M, et al. Among authors: schieppati f. Transplantation. 2016 Dec;100(12):e147-e155. doi: 10.1097/TP.0000000000001466. Transplantation. 2016. PMID: 27861297
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years.
Polverelli N, Malagola M, Turra A, Skert C, Perucca S, Chiarini M, Cattina F, Rambaldi B, Cancelli V, Morello E, Schieppati F, Bernardi S, Zanaglio C, Sottini A, Giustini V, Imberti L, Montanelli A, Russo D. Polverelli N, et al. Among authors: schieppati f. Leuk Lymphoma. 2018 Nov;59(11):2700-2705. doi: 10.1080/10428194.2018.1439584. Epub 2018 Mar 12. Leuk Lymphoma. 2018. PMID: 29527964 Clinical Trial. No abstract available.
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.
Schieppati F, Russo L, Marchetti M, Barcella L, Cefis M, Gomez-Rosas P, Caldara G, Carpenedo M, D'Adda M, Rambaldi A, Savignano C, Billio A, Bruno Franco M, Toschi V, Falanga A. Schieppati F, et al. Am J Hematol. 2020 Aug;95(8):953-959. doi: 10.1002/ajh.25845. Epub 2020 May 21. Am J Hematol. 2020. PMID: 32350923 Free article.
30 results